Singapore markets closed
Straits Times Index
3,095.59 -6.62 (-0.21%) Nikkei
25,935.62 -457.42 (-1.73%) Hang Seng
21,859.79 -137.10 (-0.62%) FTSE 100
7,168.65 -0.63 (-0.01%) BTC-USD
19,184.76 -49.49 (-0.26%) CMC Crypto 200
420.84 +0.70 (+0.17%)
Orphazyme A/S (OZYMF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 03:20PM EDT
| Previous close | 0.3906 |
| Open | 0.3906 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.3906 - 0.3906 |
| 52-week range | 0.1694 - 8.1500 |
| Volume | |
| Avg. volume | 442 |
| Market cap | 13.793M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.5370 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
- Zacks
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
- Zacks
All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
© 2022 Yahoo. All rights reserved.
